Management of uveitis in pediatric patients: special considerations

Area of Science:

• Ophthalmology
• Pediatric Medicine
• Immunology

Background:

• Uveitis involves inflammation of the uvea, the eye's middle layer.
• Pediatric uveitis (in patients ≤16 years) presents unique challenges including poor prognosis and systemic associations.
• Accurate diagnosis is crucial, necessitating comprehensive history, ophthalmic exams, and exclusion of infections or masquerade syndromes.

Purpose of the Study:

• To review the diagnosis and management of pediatric uveitis.
• To highlight age-related treatment considerations and the use of immunosuppressive agents.
• To discuss the efficacy and safety of various treatment options in children.

Main Methods:

• Review of diagnostic approaches including patient/parent history, ophthalmic examination, and investigations.
• Discussion of treatment strategies for noninfectious anterior and posterior uveitis in children.
• Analysis of commonly used immunosuppressive agents such as methotrexate and cyclosporine, and newer biologic agents.

Main Results:

• Noninfectious anterior uveitis typically responds to topical corticosteroids and mydriatics.
• Systemic corticosteroids carry risks in children (e.g., growth retardation), leading to the use of corticosteroid-sparing agents for posterior uveitis.
• Methotrexate is a frequently used, effective, and well-tolerated systemic immunosuppressant for pediatric uveitis.

Conclusions:

• Pediatric uveitis requires specialized diagnostic and therapeutic approaches.
• Corticosteroid-sparing immunosuppressants, particularly methotrexate, are essential for managing vision-threatening pediatric uveitis.
• Further randomized clinical trials are needed to establish the relative efficacy of different treatment options.